ライフサイエンスコーパス: rapamycin

1 reated animals compared with those receiving rapamycin.

2 and stably be expanded in vitro even without rapamycin.

3 th full-length FKBP or FRB, respectively, by rapamycin.

4 te EVs, could be countered by treatment with rapamycin.

5 FKBP12 ternary complexes formed by FK506 and rapamycin.

6 in analog 40x more selective for mTORC1 than rapamycin.

7 S6 kinase similar to the autophagy activator rapamycin.

8 of the antidepressant effects of ketamine by rapamycin.

9 d cyclosporine A for 28 days and 14 received rapamycin.

10 03) and mammalian target of rapamycin (mTOR [rapamycin]).

11 Mice were injected with either PBS, free rapamycin (5 mg/kg), or rapamycin-loaded leukosomes (Leu

12 de were randomized to pretreatment with oral rapamycin (6 mg) or placebo 2 h prior to the intravenous

13 g site hotspot map for the immunosuppressant rapamycin, a complex macrocyclic natural product that fo

14 tion of cortical ER following treatment with rapamycin, a drug that mimics starvation.

15 mpanied by reduced mTOR (mammalian target of rapamycin) activity and maladaptive cardiac remodeling w

16 ted the protein kinase B-mammalian target of rapamycin (AKT-mTOR) pathway, increased aerobic glycolys

17 osphoinositide 3-kinases/mammalian target of rapamycin/Akt pathway (PI3K-mTOR-AKT)-related genes.

18 0.3 x 10(6) IU/m(2) or 1 x 10(6) IU/m(2)) or rapamycin alone (0.5-1 mg/kg) for 3 weeks did not prolon

19 red with untreated mice (30.2+/-13.34 %) and rapamycin alone (26.8+/-9.87 %).

20 AMPK inhibits mTOR, and the mTOR inhibitor rapamycin also decreases NaCT expression.

21 cle cell (SMC) and macrophage proliferation; rapamycin also reduced both M1 and M2 type macrophages.

22 The mTORC1 inhibitor rapamycin also reduced IL-6 and IL-13 production, which

23 harmacological stimulation of autophagy with rapamycin also rescued the lethality caused by rrp4 inac

24 llular autophagic flux - mammalian target of rapamycin, AMP-activated protein kinase and sirtuins are

25 g pharmacological tools, we investigated how rapamycin, an inducer of autophagy, affects regeneration

26 Chloroquine and rapamycin, an inhibitor and an activator of autophagy, r

27 sis, depressed patients were pretreated with rapamycin, an mTORC1 inhibitor, prior to receiving ketam

28 identification of DL001, a FKBP12-dependent rapamycin analog 40x more selective for mTORC1 than rapa

29 pared with cells incubated with rapamycin or rapamycin and all-trans retinoic acid.

30 g cells from patients with CD incubated with rapamycin and an agonist of RARA (RAR568) expressed high

31 that combining low doses of IL-2 cplxs with rapamycin and blockade of the inflammatory cytokine IL-6

32 Although rapamycin and its analogues (rapalogs) are FDA-approved

33 ents, as illustrated by the successful drugs rapamycin and lenalidomide.

34 the mammalian target of rapamycin inhibitor rapamycin, and cells with inactivating mutations in TP53

35 amino acid starvation, nutrient deprivation, rapamycin, and lipopolysaccharide.

36 These compounds are more potent than rapamycin, and robustly downregulate phosphorylated and

37 developed as a diazirine-based PAL probe for rapamycin, and the FKBP12-photo-rapamycin-FRB ternary co

38 tinib, the mTOR complex 1 (mTORC1) inhibitor rapamycin, and the glycogen synthase kinase-3 (GSK-3) in

39 tic cells in combination with anti-CD40L and rapamycin, and this treatment leads to significant prolo

40 Taken together, rapamycin attenuated PEC proliferation and the formation

41 or of PI3K-Akt, by short-term application of rapamycin attenuated the effects of M1 receptors on GluA

42 eated with TOR-specific chemical inhibitors (rapamycin, AZD8055 and Torin1), after which differential

43 ein (FKBP) and circular permutants of FKBP12-rapamycin binding domain (cpFRB).

44 tools such as the FK506-binding protein-FKBP-rapamycin-binding- (FKBP-FRB)-rapamycin system have been

45 C infusion of the selective mTORC1 inhibitor rapamycin blocked the antidepressant actions of d-methad

46 Life span impairment by HPF1 was buffered by rapamycin but not by calorie restriction.

47 ), which was mediated by mammalian target of rapamycin C1 (mTORC1).

48 As rapamycin can attenuate bladder smooth muscle hypertroph

49 Cs can arise from pre-existing LECs and that rapamycin can prevent the growth of bone lymphatics.

50 Last, we show that rapamycin can suppress the growth of bone lymphatics in

51 metics, dis-inhibitors (the mTORC1 inhibitor rapamycin), cardiotonic steroids (the Na(+)/K(+)-ATPase

52 Furthermore, treatment with rapamycin caused an impairment in the cardiac regenerati

53 ic acid accumulation and mammalian target of rapamycin complex 1 (mTORC1) activation, which were asso

54 e lysosome to activate mechanistic target of rapamycin complex 1 (mTORC1) and cell growth-regulating

55 hed NF2 loss activates mechanistic target of rapamycin complex 1 (mTORC1) and mechanistic target of r

56 gnaling, including the mechanistic target of rapamycin complex 1 (mTORC1) and mitogen-activated prote

57 ice by activation of the mammalian target of rapamycin complex 1 (mTORC1) caused early drusen-like pa

58 Mechanistic target of rapamycin complex 1 (mTORC1) controls cell growth and pr

59 The mechanistic (or mammalian) target of rapamycin complex 1 (mTORC1) controls cell growth, proli

60 determine the roles of mechanistic target of rapamycin complex 1 (mTORC1) in regulating macrophage fu

61 The mechanistic target of rapamycin complex 1 (mTORC1) integrates growth, nutrient

62 The mechanistic target of rapamycin complex 1 (mTORC1) is a key metabolic hub that

63 We hypothesized that mechanistic Target of Rapamycin Complex 1 (mTORC1) is a positive regulator of

64 The mechanistic target of rapamycin complex 1 (mTORC1) is a well-conserved negativ

65 ynaptic plasticity via Mechanistic Target Of Rapamycin Complex 1 (mTORC1) is crucial for hippocampal

66 acid-induced lysosomal mechanistic target of rapamycin complex 1 (mTORC1) localization through the Ra

67 The mammalian Target of Rapamycin complex 1 (mTORC1) nutrient-sensing pathway is

68 and activation of the mechanistic target of rapamycin complex 1 (mTORC1) occur on the lysosome surfa

69 The Hippo and mammalian target of rapamycin complex 1 (mTORC1) pathways are the two predom

70 Mammalian target of rapamycin complex 1 (mTORC1) promotes cell growth and pr

71 dent activation of the mechanistic target of rapamycin complex 1 (mTORC1) protein kinase via its guan

72 ce the activity of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway, potentia

73 nputs that converge onto mammalian target of rapamycin complex 1 (mTORC1) signaling pathways.

74 ntify protein synthesis, mammalian target of rapamycin complex 1 (mTORC1) signaling, and autophagy ma

75 ghtly regulated by the mechanistic target of rapamycin complex 1 (mTORC1) signalling complex in respo

76 growth regulatory Akt/mechanistic Target of Rapamycin Complex 1 (mTORC1) signalling or depleting the

77 nvolves the hedgehog and mammalian target of rapamycin complex 1 (mTORC1) signalling pathways.

78 tain activation of the mechanistic target of rapamycin complex 1 (mTORC1) that promotes T cell growth

79 for suppressors of the mechanistic target of rapamycin complex 1 (mTORC1).

80 d by activation of the mechanistic target of rapamycin complex 1 (mTORC1).

81 signaling through the mechanistic target of rapamycin complex 1 (mTORC1).

82 hibiting activity of the mammalian target of rapamycin complex 1 (mTORC1).

83 signals upstream of the mammalian target of rapamycin complex 1 (mTORC1).

84 complex and the nutrient-regulated target of rapamycin complex 1 (TORC1) control the integrity of the

85 Target of rapamycin complex 1 (TORC1) is a central regulator of ce

86 The target of rapamycin complex 1 (TORC1) pathway and the activity of

87 o approved inhibitors of mammalian target of rapamycin complex 1 and CDK4/6 via ALK3-mediated P-SMAD1

88 d the master regulator mechanistic target of rapamycin complex 1 kinase is activated on lysosomes in

89 ific activation of the mechanistic target of rapamycin complex 1 seems involved in the diet-induced b

90 titutive activation of mechanistic target of rapamycin complex 1 signaling.

91 protein complex mTORC1 (mammalian target of rapamycin complex 1) signaling, which decreases protein

92 metabolic signaling hub, mammalian target of rapamycin complex 1, and the downstream transcription fa

93 Rictor, a component of mechanistic target of rapamycin complex 2 (mTORC2) and suppressed insulin-indu

94 light a specific role of mammalian target of rapamycin complex 2 (mTORC2) signaling in epidermal barr

95 complex 1 (mTORC1) and mechanistic target of rapamycin complex 2 (mTORC2) signaling, leading to clini

96 HEM1 loss also blocked mechanistic target of rapamycin complex 2 (mTORC2)-dependent AKT phosphorylati

97 network surrounding Tor complex 2 (target of rapamycin complex 2; TORC2) controls growth rate and cel

98 phosphorylation of the mechanistic target of rapamycin complex downstream-target p70S6 kinase similar

99 Target of rapamycin complex-2 (TORC2), a conserved protein kinase

100 rs insulin/IGF signaling (IIS) and target of rapamycin complex1 (TORC1), was investigated to elucidat

101 ctivated protein kinase, mammalian target of rapamycin complexes, insulin-AKT, and redox signaling pa

102 n assays, and the gene expression profile of rapamycin-conditioned Treg cells by droplet-digital PCR.

103 lly reverted in vitro suppression by in vivo rapamycin-conditioned Treg cells.

104 rtial obstruction in vivo, we tested whether rapamycin could improve persistent function after releas

105 thdrawal of the combination of cuprizone and rapamycin (Cup/Rap) in C57BL/6J male mice efficiently de

106 Rapamycin decreased smooth muscle cell (SMC) and macroph

107 Rapamycin delayed CMV reactivation and ganciclovir treat

108 m the role of mTOR activation, we found that rapamycin diminished the effect of pembrolizumab-mediate

109 genomic alterations in mechanistic target of rapamycin, DNA repair and receptor tyrosine kinase pathw

110 ion status of Tregs treated with and without rapamycin during an ex vivo expansion culture.

111 ining donor apoptotic cells, anti-CD40L, and rapamycin effectively inhibits proinflammatory B cells a

112 Rapamycin efficacy was tested by pair-wise comparison of

113 nd calorie-restricted environments and under rapamycin exposure.

114 Calorie restriction and rapamycin extended life span in virtually all genotypes

115 d adhesion and spreading abnormalities while rapamycin facilitated ciliogenesis in LS patient cells.

116 resistance to 5FOA and the antifungal drugs rapamycin/FK506 (rap/FK506) and 5-fluorocytosine (5FC) w

117 rs are important for other stressors such as rapamycin, fluconazole, and hydroxyurea treatment.

118 threonine kinase mTOR (mechanistic target of rapamycin) forms the distinct protein complexes mTORC1 a

119 AL probe for rapamycin, and the FKBP12-photo-rapamycin-FRB ternary complex formed readily in vitro.

120 Standard CNI-based mammalian target of rapamycin-free immunosuppression (group A, n = 264) was

121 Rapamycin has been shown to suppress peripheral T cells

122 hat pharmacological inhibition of mTOR using Rapamycin has deleterious effects on hematopoiesis.

123 essive medication, in the context of sepsis, rapamycin has the opposite effect.

124 The combination of IL-2 and rapamycin has the potential to inhibit human islet allog

125 olecular pathways, mTOR (mammalian target of rapamycin) has been associated with diseases including n

126 s, the use of tacrolimus/mammalian target of rapamycin immunosuppression, and an acute rejection even

127 ired for sensitivity to the mTORC1 inhibitor rapamycin in breast-cancer-derived lung tumors, but not

128 ycin on lytic replication and sensitivity to rapamycin in lytic KSHV-infected cells.

129 nch density, while induction of autophagy by rapamycin increases axon branching, indicating that auto

130 amage in neurons through mammalian target of rapamycin-independent mechanisms.

131 WASp deficiency is associated with impaired rapamycin-induced autophagosome formation and traffickin

132 uR silencing in cultured IECs also prevented rapamycin-induced autophagy, which was abolished by over

133 Rapamycin-induced inhibition of mTOR robustly prevented

134 e design of cpRAPID as a circularly permuted rapamycin-inducible dimerization system composed of the

135 In further experiments, in vitro exposure to rapamycin inhibited placental glutamine and glutamate up

136 r and genetic approaches, we found that like rapamycin, inhibition of DAPK1 activity led to enhanced

137 to sirolimus (SRL), a mechanistic target of rapamycin inhibitor (mTOR-I), has been shown to enhance

138 recurrence after LT (74% mammalian target of rapamycin inhibitor [mTORi], 54% HCC-treated at baseline

139 C2 were sensitive to the mammalian target of rapamycin inhibitor rapamycin, and cells with inactivati

140 and introduction of the mammalian target of rapamycin inhibitor Sirolimus (SIR) within 4-6 weeks aft

141 calcineurin inhibitor to mammalian target of rapamycin inhibitor, and 5 patients were managed by decr

142 Cs) and the early use of mammalian target of rapamycin inhibitors after kidney transplantation (KT) h

143 e ribose) polymerase and mammalian-target-of-rapamycin inhibitors.

144 nces TORC1 activity, and the TORC1 inhibitor rapamycin inhibits clock-driven daytime growth, no effec

145 aling was specifically disrupted by deleting rapamycin-insensitive companion of target of rapamycin (

146 inal ganglion (TG) that includes Rictor, the rapamycin-insensitive complex-2 of mTOR (mTORC2), and ge

147 dylinositol 3-kinase/Akt/mammalian target of rapamycin is a key pathway of survival and therapeutic r

148 Rapamycin is able to affect Treg suppressive function vi

149 onstrate that chronic mTORC1 inhibition with rapamycin is overwhelmingly, but not entirely, positive

150 Thus, although rapamycin is typically an immunosuppressive medication,

151 se (41%) and remission rates (29%) following rapamycin + ketamine compared to placebo + ketamine (13%

152 Mechanistic target of rapamycin kinase (MTOR) and erythroblastosis oncogene B

153 a yeast cell is controlled by the target of rapamycin kinase complex I (TORC1) and cAMP-dependent pr

154 on is sensitive to mTOR (mammalian target of rapamycin) kinase activity.

155 ith either PBS, free rapamycin (5 mg/kg), or rapamycin-loaded leukosomes (Leuko-Rapa; 5 mg/kg) once d

156 Rapamycin-loaded nanoparticles were characterized using

157 ketamine, provides preliminary evidence that rapamycin may extend the benefits of ketamine, and there

158 f-principle experiments are provided for the rapamycin-mediated association between FKBP12 and FRB, a

159 biting LAT1 (JPH203) and mammalian target of rapamycin (mTOR [rapamycin]).

160 sses lncRNAs and impairs mammalian target of rapamycin (mTOR) activation.

161 ssociated with increased mammalian target of rapamycin (mTOR) activity and also with decreased produc

162 ongside the reduction in mammalian target of rapamycin (mTOR) activity and restriction in CD4(+) T ce

163 eatment also antagonized mammalian target of rapamycin (mTOR) activity and was associated with increa

164 und that Treg have low mechanistic target of rapamycin (mTOR) activity and would be less dependent on

165 duct of declining LIN28B-mammalian target of rapamycin (mTOR) activity.

166 cation to stimulation of mammalian target of rapamycin (mTOR) activity; DNA repair, splicing, and tra

167 The mammalian target of rapamycin (mTOR) and associated phosphatidylinositol 3-k

168 sosomal processes, and mechanistic target of rapamycin (mTOR) and cytokine pathways are up-regulated

169 aling pathways involving mammalian target of rapamycin (mTOR) and lysophosphatidylcholine acyltransfe

170 ol-related decrease in mechanistic target of rapamycin (mTOR) and Ras homolog enriched in brain (Rheb

171 Moreover, inhibiting the mammalian target of rapamycin (mTOR) complex 1, an important downstream effe

172 ntially dependent on the mammalian target of rapamycin (mTOR) for proliferation and the lipid peroxid

173 The mammalian target of rapamycin (mTOR) functions as two complexes (mTORC1 and

174 In ATP7B-knockout cells, mammalian target of rapamycin (mTOR) had decreased activity and was dissocia

175 ver, inhibition of the mechanistic target of rapamycin (MTOR) has cellular effects that may alter HIV

176 adipose autophagy and mechanistic target of rapamycin (mTOR) in alcohol-induced adipose and liver pa

177 s, suggesting a role for mammalian target of rapamycin (mTOR) in the formation of Trm through effects

178 d by the energy sensor mechanistic target of rapamycin (mTOR) in the muscle and liver.

179 The involvement of mammalian target of rapamycin (mTOR) in the positive regulation of oncogenes

180 ologic inhibition of the mammalian target of rapamycin (mTOR) in the setting of renal transplantation

181 d graft before and after mammalian target of rapamycin (mTOR) inhibition.

182 r GBM, and everolimus, a mammalian target of rapamycin (mTOR) inhibitor that modulates aberrant signa

183 e cancer growth, whereas mammalian target of rapamycin (mTOR) inhibitors like sirolimus have anticanc

184 e deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors were designed and synthesize

185 the inhibition of the mechanistic target of rapamycin (MTOR) inhibits HIV replication in human macro

186 Mechanistic target of rapamycin (MTOR) is a highly conserved serine/threonine

187 ing by the mechanistic (mammalian) target of rapamycin (mTOR) kinase is important for cell survival a

188 egative control of the mechanistic target of rapamycin (mTOR) pathway and independent of alterations

189 activating mutations of mammalian target of rapamycin (mTOR) pathway genes are emerging as a major c

190 ogenic variants in the mechanistic target of rapamycin (mTOR) pathway genes leading to differential a

191 sitide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is frequently overactivated in

192 The mechanistic target of rapamycin (mTOR) pathway is hyperactivated in cancer and

193 GNIFICANCE STATEMENT The mammalian target of rapamycin (mTOR) pathway is strongly implicated in epile

194 nositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway represents an attractive therap

195 including members of the mammalian target of rapamycin (mTOR) pathway.

196 0 production via the Akt/mammalian target of rapamycin (mTOR) pathway.

197 The protein kinase mechanistic target of rapamycin (mTOR) performs diverse cellular functions thr

198 The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumo

199 pe is similar to that of mammalian target of rapamycin (mTOR) protein kinase deletion or mTOR inhibit

200 ctors that contribute to mammalian target of rapamycin (mTOR) signaling activation and identify novel

201 rvival by activating the mammalian target of rapamycin (mTOR) signaling and blocking ER stress.

202 ells as well as impaired mammalian target of rapamycin (mTOR) signaling and interferon-alpha (IFN-alp

203 Excessive activation of mammalian target of rapamycin (mTOR) signaling is epileptogenic in genetic e

204 e aberrant activation of mammalian target of rapamycin (mTOR) signaling networks plays a central role

205 ression, and propose the mammalian target of rapamycin (mTOR) signaling pathway as a candidate mechan

206 The mechanistic target of rapamycin (mTOR) signaling pathway has been implicated i

207 The mammalian Target of Rapamycin (mTOR) signaling pathway is active in human oR

208 hyperactivation of the mechanistic target of rapamycin (mTOR) signaling pathway is the primary cause

209 /Akt (protein kinase B)/ mammalian target of rapamycin (mTOR) signaling pathway.

210 ion capacity mediated by mammalian target of rapamycin (mTOR) signaling that directly contributes to

211 ase with overactivated mechanistic target of rapamycin (mTOR) signaling, has demonstrated the therape

212 Dysregulation of the mammalian target of rapamycin (mTOR) signaling, which is mediated by two str

213 t leads to activation of mammalian target of rapamycin (mTOR) signaling.

214 ctivity of insulin and mechanistic target of rapamycin (mTOR) signalling, which are involved in regul

215 e-specific deletion of mechanistic target of rapamycin (mTOR) to demonstrate that mTOR regulates expr

216 n signaling intersect at mammalian target of rapamycin (mTOR), a critical node for cell proliferation

217 Tsc1, which inhibits the mammalian target of rapamycin (MTOR), causes a subset of SST+ CINs, to expre

218 nositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR)-dependent protein kinase B (AKT) signal

219 SG formation include the mammalian target of rapamycin (mTOR)-eukaryotic translation initiation facto

220 ed protein kinase (AMPK)-mammalian target of rapamycin (mTOR)-S6 kinase-dependent manner in LXA4-trea

221 The mechanistic target of rapamycin (mTOR)-signaling pathway plays a key role in n

222 -alpha (PPAR-alpha), and mammalian target of rapamycin (mTOR).

223 tric oxide synthase, and mammalian target of rapamycin (mTOR).

224 emerged for mechanistic/mammalian target of rapamycin (mTOR).

225 hagosomal recruitment of mammalian target of rapamycin (mTOR).

226 ional regulatory complex mammalian target of rapamycin (mTOR).(,) These studies represent a major shi

227 calcineurin inhibitors, mammalian target of rapamycin [mTOR] inhibitors, belatacept, induction agent

228 crosstalk between the mechanistic target of rapamycin, mTOR and JAs.

229 Activation of autophagy by rapamycin noticeably reduced the AGR2 protein in cells a

230 cation and enhances the inhibitory effect of rapamycin on lytic replication and sensitivity to rapamy

231 ic inhibition of mTOR (mechanistic target of rapamycin) on resistance of CSCs to cisplatin, a prototy

232 esis was reduced after mTOR inhibition using rapamycin or autophagy inhibition using 3-methyladenine.

233 t can be allosterically controlled by either rapamycin or blue light, as well as experimental procedu

234 nd FOXP3, compared with cells incubated with rapamycin or rapamycin and all-trans retinoic acid.

235 Blocking the mammalian target of rapamycin or reactivating peroxisome proliferator-activa

236 in the presence of mTOR inhibitors, such as rapamycin or torin1, had minimal impact on the degree of

237 Rapamycin partially inhibited human, baboon, and pig IL-

238 vation of the PI3K-AKT-mechanistic target of rapamycin pathway and underlie a novel inborn error of i

239 ion of proteins in the mechanistic target of rapamycin pathway were similar in control and IUGR skele

240 e) gene, part of the p53/mammalian target of rapamycin pathway, was due to nonrandom distribution of

241 inase-protein kinase B-mechanistic target of rapamycin pathway: gper1-knockout and mtor-knockout zebr

242 Rapamycin pretreatment did not alter the antidepressant

243 In summary, single dose rapamycin pretreatment failed to block the antidepressan

244 echanistic Target Of Rapamycin) signaling by rapamycin promotes healthspan and longevity more strongl

245 istinct conformations of complex-bound photo-rapamycin, providing a 5.0 angstrom distance constraint

246 (short) or 21-day (long) culture with EVR or rapamycin (RAPA).

247 lls in Cd1d-/- mice or inhibition of mTOR by rapamycin reduced immunosuppression and susceptibility t

248 that treatment of iPSC-derived neurons with rapamycin reduced neuronal activity and partially revers

249 gineered islet grafts with a short course of rapamycin regimen resulted in sustained graft survival a

250 e demonstrate that short-term treatment with rapamycin rejuvenates the aged oral cavity of elderly mi

251 -obstruction, REL animals were randomized to rapamycin (REL+rapa) or vehicle (REL+veh).

252 Inhibiting mTOR activity with rapamycin rescued the generation of Foxp3(+) T cells.

253 Pretreating cells with mTORC1 inhibitor rapamycin restored BCKA's effect on insulin-induced AKT

254 Inhibition of mTOR kinase by Torin1 or rapamycin results in reduction in ZIKV protein expressio

255 rapamycin-insensitive companion of target of rapamycin (Rictor), encoding an essential subunit of mTO

256 Peritransplant CD154 mAb/rapamycin (RPM) induced long-term orthotopic hindlimb VC

257 cal, results, in which the top tier includes rapamycin, senolytics, metformin, acarbose, spermidine,

258 a decline in pulmonary function, increase of rapamycin-sensitive expression of WNT ligands, and profo

259 tuated downstream of the mammalian target of rapamycin signaling pathway.

260 Inhibition of mTOR (mechanistic Target Of Rapamycin) signaling by rapamycin promotes healthspan an

261 activation of the mTOR (mammalian target of rapamycin) signaling pathway, but little is known on how

262 mTORC1 inhibition with rapamycin significantly improved survival of CKO animals

263 Moreover, treatment with rapamycin significantly increased the concentrations of

264 udy we questioned whether the mTOR inhibitor rapamycin (sirolimus) could attenuate the development an

265 The FDA-approved drug rapamycin slows aging and extends lifespan in multiple o

266 Inhibiting mTOR with rapamycin suppressed the growth of subcutaneous MET-muta

267 g protein-FKBP-rapamycin-binding- (FKBP-FRB)-rapamycin system have been widely used to probe molecula

268 ism while inhibiting the mammalian target of rapamycin targets p70S6K and 4EBP1, with decreased cytok

269 t media, but not when cells are treated with rapamycin, the allosteric inhibitor of mTORC1.

270 from MSCs, and consequently, the addition of rapamycin to an isoniazid treatment regimen successfully

271 hibition of autophagy impairs the ability of rapamycin to mediate improved gut health and proteostasi

272 interleukin-2 (IL-2) combined with low-dose rapamycin to prolong graft survival.

273 Use biomimetic nanoparticles to deliver rapamycin to the vessel wall to reduce inflammation in a

274 nstrate that the crosstalk between Target of Rapamycin (TOR) and Fibroblast growth factor receptor b

275 se-related protein kinases (PIKKs) target of rapamycin (TOR) has been established as a central hub fo

276 Target of rapamycin (TOR) is a protein kinase that coordinates euk

277 Target of rapamycin (TOR) is a protein kinase that coordinates met

278 sucrose and partially dependent on TARGET OF RAPAMYCIN (TOR) kinase activity.

279 ere mitigated by inhibition of the Target of Rapamycin (TOR) kinase signaling pathway.

280 nt sensing mechanisms, through the target of rapamycin (TOR) pathway.

281 tem cell proliferation mediated by Target Of Rapamycin (TOR) signaling.

282 -ligated (IIS-, TORC1- and JH-deficient) and rapamycin-treated (TORC1- and JH-deficient) cockroaches.

283 nd function of FOXP3-mutated Treg cells from rapamycin-treated patients with IPEX syndrome were teste

284 ations in this screening platform, including rapamycin treatment and genetic ablation of the Ragulato

285 LOCK and NPAS2 expression above sham levels, rapamycin treatment during release significantly blocked

286 basis of the clinical benefit observed under rapamycin treatment in 6 patients with IPEX syndrome wit

287 Strikingly, rapamycin treatment in the first 8 postnatal days amelio

288 The decrease in lung Trm following early rapamycin treatment is accompanied by increased circulat

289 bserved in patients with IPEX syndrome under rapamycin treatment.

290 ion in human parietal epithelial cells after rapamycin treatment.

291 in contrast to treatment with vigabatrin and rapamycin, TrkB inhibition rescued brain dysconnectivity

292 Through localized delivery of rapamycin via a biomimetic drug delivery system, it is p

293 ssue expression of the mechanistic target of rapamycin was 13% lower, whereas the mitochondrial respi

294 Rapamycin was associated with improved long-term patency

295 Photo-rapamycin was developed as a diazirine-based PAL probe f

296 mTORC1 inhibitor, rapamycin, was able to rescue the impaired autophagy in

297 Finally, using the mTORC1 inhibitor rapamycin, we demonstrate that LIN28B promotes supportin

298 was found to be reversible by treatment with rapamycin, which then enhanced PPMS NPC support for olig

299 However, the combination of rapamycin with IL-2 for 3 weeks significantly prolonged

300 zures, including for up to 40 days following rapamycin withdrawal.